MedTrace Logo

Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma

NCT00002748 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2011-10-04

No results posted yet for this study

Summary

RATIONALE: Inserting the gene for interleukin-2 into a person's neuroblastoma cells may make the body build an immune response and kill tumor cells.

PURPOSE: Phase I trial to study the effectiveness of using interleukin-2 gene-modified neuroblastoma cells in treating children who have refractory or recurrent neuroblastoma.

Conditions

Interventions

BIOLOGICAL

gene-modified tumor cell vaccine therapy

BIOLOGICAL

interleukin-2 gene

Sponsors & Collaborators

Principal Investigators

  • Gregory Hale, MD · St. Jude Children's Research Hospital

Study Design

Purpose
TREATMENT

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-12-31
Primary Completion
2007-08-31
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002748 on ClinicalTrials.gov